Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 26, 2026

New Crypto Pepeto Advances DeFi Tools While Bitcoin Price Target $180,000 and Whales Load Next Dogecoin

View original at globenewswire.com
New Crypto Pepeto Advances DeFi Tools While Bitcoin Price Target $180,000 and Whales Load Next Dogecoin Dubai, UAE, July 26, 2026 (GLOBE NEWSWIRE) -- Pepeto is preparing a revolution in DeFi trading with its zero-fee exchange, and the timing is making considering presales, the crypto side that hands most of returns dur…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Truth API is priced at up to $100,000 per month, with a $60,000 rate for three-year commitments.

    60% confidence

  • Bitcoin price prediction target of $180,000.

    60% confidence

  • A sitting congressman is asking regulators whether selling early access to presidential posts breaks manipulation rules.

    60% confidence

  • The president's social media posts move markets, so market participants pay for early access.

    60% confidence

  • $1,000 invested in Dogecoin in March 2020 became $365,000 by May 2021, a 365x return.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
New Crypto Pepeto Advances DeFi Tools While Bitcoin Price Target $180,000 and Whales Load Next Dogecoin — Source | Via News | ViaNews EU